Do analysts recommend GOVX or NMTR?

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than 9 Meters Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or NMTR more profitable?

9 Meters Biopharma's return on equity of -584.97% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts recommend PPCB or NMTR?

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, PPCB or NMTR?

Propanc Biopharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is PPCB or NMTR more profitable?

Propanc Biopharma's return on equity of -151.28% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% 9 Meters Biopharma N/A -584.97% -159.45%

Do analysts rate CAPS or NMTR?

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Capstone Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer NMTR or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than 9 Meters Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, NMTR or DCOY?

Decoy Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is NMTR or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets 9 Meters Biopharma N/A -584.97% -159.45% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts recommend UPC or NMTR?

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, UPC or NMTR?

Universe Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.20 -$3.67M N/A N/A 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Is UPC or NMTR more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A 9 Meters Biopharma N/A -584.97% -159.45%

9 Meters Biopharma (NMTR) Competitors

Compare

NMTR vs. GOVX, PPCB, CAPS, DCOY, and UPC

Should you buy 9 Meters Biopharma stock or one of its competitors? MarketBeat compares 9 Meters Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 9 Meters Biopharma include GeoVax Labs (GOVX), Propanc Biopharma (PPCB), Capstone Therapeutics (CAPS), Decoy Therapeutics (DCOY), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical products" industry.

How does 9 Meters Biopharma compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, GeoVax Labs had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for 9 Meters Biopharma. GeoVax Labs' average media sentiment score of 0.49 beat 9 Meters Biopharma's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
9 Meters Biopharma	Neutral

GeoVax Labs has higher revenue and earnings than 9 Meters Biopharma. GeoVax Labs is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

9 Meters Biopharma's return on equity of -584.97% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

GeoVax Labs beats 9 Meters Biopharma on 7 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

In the previous week, Propanc Biopharma had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Propanc Biopharma and 0 mentions for 9 Meters Biopharma. Propanc Biopharma's average media sentiment score of 0.86 beat 9 Meters Biopharma's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Propanc Biopharma	Positive
9 Meters Biopharma	Neutral

Propanc Biopharma has a beta of 3.49, meaning that its stock price is 249% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Propanc Biopharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

22.3% of 9 Meters Biopharma shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Propanc Biopharma's return on equity of -151.28% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

Propanc Biopharma beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Capstone Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

9 Meters Biopharma has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
9 Meters Biopharma	N/A	-584.97%	-159.45%

In the previous week, Capstone Therapeutics' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Capstone Therapeutics	Neutral
9 Meters Biopharma	Neutral

Capstone Therapeutics has higher revenue and earnings than 9 Meters Biopharma. Capstone Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$51.62M	0.08	-$21.23M	-$3.37	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Capstone Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.5% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Capstone Therapeutics beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Decoy Therapeutics?

9 Meters Biopharma (NASDAQ:NMTR) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Decoy Therapeutics' return on equity of -395.42% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
Decoy Therapeutics	N/A	-395.42%	-193.30%

In the previous week, Decoy Therapeutics had 5 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 5 mentions for Decoy Therapeutics and 0 mentions for 9 Meters Biopharma. Decoy Therapeutics' average media sentiment score of 0.22 beat 9 Meters Biopharma's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
9 Meters Biopharma	Neutral
Decoy Therapeutics	Neutral

9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Decoy Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Summary

Decoy Therapeutics beats 9 Meters Biopharma on 7 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Universe Pharmaceuticals had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Universe Pharmaceuticals' average media sentiment score of 0.08 beat 9 Meters Biopharma's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
9 Meters Biopharma	Neutral

Universe Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
9 Meters Biopharma	N/A	-584.97%	-159.45%

Universe Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Universe Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.20	-$3.67M	N/A	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Given 9 Meters Biopharma's higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Universe Pharmaceuticals beats 9 Meters Biopharma on 9 of the 11 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTR vs. The Competition

Export

Metric	9 Meters Biopharma	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04M	$431.50M	$7.16B	$12.48B
Dividend Yield	N/A	3.88%	2.66%	6.52%
P/E Ratio	0.00	3.09	28.02	24.70
Price / Sales	N/A	6,669.11	540.55	99.42
Price / Cash	N/A	13.13	49.26	57.09
Price / Book	N/A	88.67	10.96	6.46
Net Income	-$43.77M	-$96.07M	$3.57B	$337.01M

9 Meters Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$1.04M	N/A	N/A	20
GOVX GeoVax Labs	2.6784 of 5 stars	$1.19 -5.6%	$150.00 +12,505.0%	-90.1%	$4.13M	$2.49M	N/A	10
PPCB Propanc Biopharma	0.7979 of 5 stars	$1.77 +22.9%	N/A	-98.3%	$4.03M	N/A	N/A	1	News Coverage Buyback Announcement Gap Up High Trading Volume
CAPS Capstone Therapeutics	0.8771 of 5 stars	$0.26 -4.7%	N/A	-82.7%	$3.97M	$51.62M	N/A	38	Positive News Analyst Upgrade
DCOY Decoy Therapeutics	3.0473 of 5 stars	$7.31 -4.1%	$30.00 +310.4%	N/A	$3.87M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

9 Meters Biopharma (NMTR) Competitors

NMTR vs. GOVX, PPCB, CAPS, DCOY, and UPC

How does 9 Meters Biopharma compare to GeoVax Labs?

Summary

How does 9 Meters Biopharma compare to Propanc Biopharma?

Summary

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Summary

How does 9 Meters Biopharma compare to Decoy Therapeutics?

Summary

How does 9 Meters Biopharma compare to Universe Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

9 Meters Biopharma (NMTR) Competitors

NMTR vs. GOVX, PPCB, CAPS, DCOY, and UPC

How does 9 Meters Biopharma compare to GeoVax Labs?

Does the media prefer GOVX or NMTR?

Which has higher valuation and earnings, GOVX or NMTR?

Do insiders and institutionals believe in GOVX or NMTR?

Which has more risk & volatility, GOVX or NMTR?

Do analysts recommend GOVX or NMTR?

Is GOVX or NMTR more profitable?

Summary

How does 9 Meters Biopharma compare to Propanc Biopharma?

Does the media prefer PPCB or NMTR?

Which has more risk and volatility, PPCB or NMTR?

Which has preferable earnings & valuation, PPCB or NMTR?

Do institutionals & insiders believe in PPCB or NMTR?

Do analysts recommend PPCB or NMTR?

Is PPCB or NMTR more profitable?

Summary

How does 9 Meters Biopharma compare to Capstone Therapeutics?

Which has more volatility and risk, CAPS or NMTR?

Is CAPS or NMTR more profitable?

Does the media prefer CAPS or NMTR?

Which has stronger earnings & valuation, CAPS or NMTR?

Do analysts rate CAPS or NMTR?

Do institutionals & insiders believe in CAPS or NMTR?

Summary

How does 9 Meters Biopharma compare to Decoy Therapeutics?

Do institutionals and insiders believe in NMTR or DCOY?

Do analysts prefer NMTR or DCOY?

Is NMTR or DCOY more profitable?

Does the media prefer NMTR or DCOY?

Which has more risk and volatility, NMTR or DCOY?

Which has stronger earnings and valuation, NMTR or DCOY?

Summary

How does 9 Meters Biopharma compare to Universe Pharmaceuticals?

Does the media refer more to UPC or NMTR?

Is UPC or NMTR more profitable?

Which has more risk and volatility, UPC or NMTR?

Do insiders & institutionals hold more shares of UPC or NMTR?

Which has higher earnings & valuation, UPC or NMTR?

Do analysts recommend UPC or NMTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTR vs. The Competition

9 Meters Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools